Oxford Immunotec (OXFD) Tops Q4 EPS by 17c

Oxford Immunotec (NASDAQ: OXFD) reported Q4 EPS of ($0.22), $0.17 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $23.7 million versus the consensus estimate of $22.92 million.

GUIDANCE:

Oxford Immunotec sees Q1 2017 revenue of $20.8-21.3 million.

Oxford Immunotec sees FY2017 revenue of $102-105 million.

For earnings history and earnings-related data on Oxford Immunotec (OXFD) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49